Corient Private Wealth LLC Boosts Holdings in Gossamer Bio, Inc. $GOSS

Corient Private Wealth LLC boosted its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 19,123.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,845,885 shares of the company’s stock after buying an additional 3,825,879 shares during the quarter. Corient Private Wealth LLC’s holdings in Gossamer Bio were worth $11,922,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc purchased a new stake in Gossamer Bio in the second quarter worth about $26,000. Banco BTG Pactual S.A. purchased a new stake in shares of Gossamer Bio in the second quarter worth $27,000. MMA Asset Management LLC bought a new stake in shares of Gossamer Bio during the 4th quarter valued at $31,000. Soltis Investment Advisors LLC purchased a new position in shares of Gossamer Bio during the 4th quarter valued at $31,000. Finally, Beacon Pointe Advisors LLC purchased a new position in shares of Gossamer Bio during the 4th quarter valued at $34,000. 81.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wedbush reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. Oppenheimer cut their target price on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Gossamer Bio in a research note on Tuesday, May 26th. Finally, The Goldman Sachs Group downgraded Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.00.

Gossamer Bio Stock Up 4.4%

GOSS opened at $0.17 on Wednesday. The firm has a 50-day simple moving average of $0.27 and a two-hundred day simple moving average of $1.33. Gossamer Bio, Inc. has a 52 week low of $0.14 and a 52 week high of $3.87. The company has a market capitalization of $40.23 million, a PE ratio of -0.22 and a beta of 2.00.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.95 million during the quarter, compared to analysts’ expectations of $4.67 million. As a group, sell-side analysts expect that Gossamer Bio, Inc. will post -0.45 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.